CTOs on the Move


 
Aziyo Biologics is a fully integrated, commercially oriented regenerative medicine company. Since its founding in 2015 the Company has expanded through acquisitions and strategic partnerships, creating a high growth commercial entity. Its proprietary products are used in orthopedic, cardiovascular and other medical specialties.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.aziyo.com
  • 12510 Prosperity Drive Suite 370
    Silver Spring, MD USA 20904
  • Phone: 240.247.1170

Executives

Name Title Contact Details

Funding

Aziyo raised $10M on 08/06/2018

Similar Companies

The Headline Salon- Hair Salons

The Headline Salon- Hair Salons is a Woodland Hills, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Point Medical Corporation

Point Medical Corporation is a Crown Point, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Avista Healthcare

Avista Healthcare is a Cherry Hill, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

DNA Direct

DNA Direct is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Beyond Air

Beyond Air, Inc. is a clinical-stage medical device and biopharmaceutical company developing a revolutionary NO Generator and Delivery System, LungFit®, that uses NO generated from ambient air to deliver precise amounts of NO to the lungs for the potential treatment of a variety of pulmonary diseases. The LungFit® can generate up to 400 ppm of NO, for delivery either continuously or for a fixed amount of time and has the ability to either titrate dose on demand or maintain a constant dose. The Company is currently applying its therapeutic expertise to develop treatments for pulmonary hypertension in various settings, in addition to treatments for respiratory tract infections that are not effectively addressed with current standards of care. Beyond Air is currently advancing its revolutionary LungFit® for clinical trials for the treatment of severe lung infections such as acute viral pneumonia (including COVID-19) and nontuberculous mycobacteria (NTM). Additionally, Beyond Air is using ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting.